Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Swiss Medica
Belgrade, Serbiastartstemcells.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Swiss Medica has treated over 10,000 patients from more than 70 countries with stem cell therapies for a range of chronic, neurological, autoimmune, and orthopedic conditions. Reported outcomes include reduced pain, improved motor control and mobility, fewer symptom flare-ups, greater independence in daily life, and overall better quality of life. The company emphasizes personalized care combining mesenchymal stem cells with supportive therapies to enhance regenerative potential
- Therapeutic areas
- EndocrinologyPsychiatryNeurology
- Modalities
- Stem cell therapy (specifically Mesenchymal stem cells)Cell therapyRegenerative medicine approaches
- Industry
- Non-Academic Healthcare
Beyond the preview
Go deeper on Swiss Medica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Swiss Medica.